What Does Silverback Therapeutics Do?

Total employees65
HeadquartersSeattle
Founded2016

Silverback Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC™ technology platform to develop tissue-targeted therapeutics for the treatment of cancer, viral, and fibrotic diseases. Founded in 2016, the company aimed to create potent, locally-acting therapies to improve patient outcomes while minimizing systemic toxicities. In March 2022, Silverback announced a significant restructuring, discontinuing its lead programs. Subsequently, in November 2022, Silverback Therapeutics completed a reverse merger with ARS Pharmaceuticals, with ARS Pharma becoming the surviving entity. Silverback's operations as an independent company ceased thereafter.

Where Is Silverback Therapeutics's Headquarters?

Silverback Therapeutics officeSilverback Therapeutics officeSilverback Therapeutics officeSilverback Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters served as the central hub for research and development, clinical operations, and corporate administration for its ImmunoTAC™ platform.

Notable Features:

Located in the South Lake Union neighborhood, known for its concentration of biotech and tech companies, offering modern lab and office spaces typical of the area. Specific architectural details of their leased suite are not widely publicized.

Work Culture:

As a clinical-stage biotech, the culture likely emphasized scientific rigor, innovation, collaboration, and a fast-paced environment focused on advancing novel therapies. This is based on typical industry culture; specific details for Silverback are limited post-merger.

HQ Significance:

The Seattle HQ was strategically important for access to talent, research institutions, and the vibrant biotech ecosystem in the Pacific Northwest during its operational years.

Values Reflected in HQ: The choice of a modern facility in a recognized biotech hub likely reflected the company's commitment to cutting-edge science, innovation, and collaboration within the life sciences community. This is an inference as specific company statements on HQ values are scarce.

Location:

As a U.S.-based clinical-stage biopharmaceutical company primarily focused on research and development, Silverback Therapeutics did not have a significant established global operational presence with international offices. Its collaborations and clinical trials might have involved international partners or sites, typical for the biotechnology industry, but its core team and physical infrastructure were concentrated in the United States prior to its merger.

Street Address:

500 Fairview Ave N, Suite 600

City:

Seattle

State/Province:

WA

Country:

USA

Where Else Does Silverback Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Silverback Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Silverback Therapeutics? Meet the Executive Team

As of April 2025, Silverback Therapeutics' leadership includes:

Laura Shawver, Ph.D. - Former Chief Executive Officer
Valerie Odegard, Ph.D. - Former President and Chief Scientific Officer
Jonathan Piazza - Former Chief Financial Officer
Naomi Hunder, M.D. - Former Chief Medical Officer
Kyle Rasbach, Ph.D., Pharm.D. - Former Chief Business Officer

Who's Investing in Silverback Therapeutics?

Silverback Therapeutics has been backed by several prominent investors over the years, including:

OrbiMed
Celgene (acquired by Bristol Myers Squibb)
UPMC Enterprises
Alexandria Venture Investments
Deerfield Management
RA Capital Management
Sutter Hill Ventures
Nextech Invest
Longitude Capital

What Leadership Changes Has Silverback Therapeutics Seen Recently?

Hire2
Exits1

In the 12-18 months preceding its merger with ARS Pharmaceuticals in late 2022, Silverback Therapeutics underwent significant strategic shifts, including program discontinuations and leadership changes. These culminated in the company ceasing independent operations via the merger.

Departures

Laura Shawver, Ph.D., Laura Shawver stepped down as CEO, remaining on the Board of Directors, as part of a company restructuring and strategic pivot.

New Appointments:

Valerie Odegard, Ph.D., Valerie Odegard was promoted to President, taking on additional leadership responsibilities while retaining her role as Chief Scientific Officer.
Dr. Russ G. Gasteiger, Dr. Russ G. Gasteiger was appointed as SVP, Head of Chemistry, Manufacturing, and Controls, a key technical leadership role.

What Technology (Tech Stack) Is Used bySilverback Therapeutics?

Discover the tools Silverback Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Silverback Therapeutics Email Formats and Examples

Common email formats for life science companies like Silverback Therapeutics historically included patterns such as [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com. As Silverback Therapeutics is no longer an active independent entity and its domain (silverbacktx.com) is inactive, these formats are purely historical references.

[first_initial][last]@silverbacktx.com

Format

jdoe@silverbacktx.com

Example

0%

Success rate

What's the Latest News About Silverback Therapeutics?

ARS Pharmaceuticals / BioSpaceNovember 23, 2022

ARS Pharmaceuticals Announces Closing of Merger with Silverback Therapeutics

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) announced the completion of its previously announced merger with Silverback Therapeutics, Inc. The combined, publicly traded company will operate under the name ARS Pharmaceuticals, Inc. and its shares will trade on the Nasdaq Global Select Market under the ticker symbol 'SPRY'. The merger positions ARS to advance its lead product candidate, neffy® (epinephrine nasal spray)....more

Silverback Therapeutics / GlobeNewswireJuly 21, 2022

Silverback Therapeutics Enters into Definitive Merger Agreement with ARS Pharmaceuticals

Silverback Therapeutics, Inc. announced it had entered into a definitive merger agreement with ARS Pharmaceuticals, Inc., a privately-held biopharmaceutical company. The combined company was to focus on advancing ARS’s pipeline of potentially life-saving allergy treatments, including its lead product candidate neffy®....more

Silverback Therapeutics / GlobeNewswireMarch 31, 2022

Silverback Therapeutics Provides Corporate Update, Discontinues Lead Programs, and Explores Strategic Alternatives

Silverback Therapeutics announced a corporate update, including the decision to discontinue development of its lead clinical programs, SBT6050 and SBT6290, and its discovery program SBT8230. The company initiated a process to explore and evaluate strategic alternatives to maximize shareholder value and also announced a reduction in its workforce by approximately 27%....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Silverback Therapeutics, are just a search away.